Elevated levels of adipokines predict outcome after acute myocardial infarction: A long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort

Diabetes and Vascular Disease Research

Volumn 14, Issue 2, 2017, Pages 77-87

  Ritsinger, Viveca ^a,b   Brismar, Kerstin ^a,c   Malmberg, Klas ^a   Mellbin, Linda ^a   Näsman, Per ^d   Rydén, Lars ^a   Söderberg, Stefan ^e   Tenerz, Åke ^f   Norhammar, Anna ^a,g  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Department of Research and Development ^*  (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

^f CENTRAL HOSPITAL   (Sweden)

^g ST GÖRAN S HOSPITAL   (Sweden)

Author keywords

Acute myocardial infarction; adipokines; diabetes; prognosis

Indexed keywords

ADIPONECTIN; GLUCOSE; LEPTIN; ADIPOQ PROTEIN, HUMAN; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER MORTALITY; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROTEIN BLOOD LEVEL; SEX; BLOOD; CAUSE OF DEATH; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; GLUCOSE INTOLERANCE; HOSPITAL DISCHARGE; INSULIN RESISTANCE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; ODDS RATIO; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL MODEL; SWEDEN; TIME FACTOR;

ADIPONECTIN; AGED; BIOMARKERS; BLOOD GLUCOSE; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INSULIN RESISTANCE; KAPLAN-MEIER ESTIMATE; LEPTIN; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PATIENT DISCHARGE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SWEDEN; TIME FACTORS;

EID: 85012104646     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164116678156     Document Type: Article

References (31)

1. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015; 36: 1163-1170.
2. Ritsinger V, Tanoglidi E, Malmberg K, et al. Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the glucose tolerance in patients with acute myocardial infarction cohort. Diab Vasc Dis Res 2015; 12: 23-32.
3. Wannamethee SG, Tchernova J, Whincup P, et al. Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters. Int J Obes (Lond) 2007; 31: 1089-1098.
4. Andreasson AN, Undén AL, Elofsson S, et al. Leptin and adiponectin: distribution and associations with cardiovascular risk factors in men and women of the general population. Am J Hum Biol 2012; 24: 595-601.
5. Zhang H, Mo X, Hao Y, et al. Adiponectin levels and risk of coronary heart disease: a meta-analysis of prospective studies. Am J Med Sci 2013; 345: 455-461.
6. Söderberg S, Ahrén B, Jansson JH, et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999; 246: 409-418.
7. Szmitko H, Teoh H, Stewart DJ, et al. Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol 2007; 292: 1655-1663.
8. Maury E, Brichard SM., Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010; 314: 1-16.
9. Kobashi C, Urakaze M, Kishida M, et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 2005; 97: 1245-1252.
10. Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105: 2893-2898.
11. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasmaprotein, adiponectin, suppresses lipid accumulation and class. A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-1063.
12. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
13. Antonopoulos AS, Margaritis M, Coutinho P, et al. Reciprocal effects of systemic inflammation and brain natriuretic peptide on adiponectin biosynthesis in adipose tissue of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 2014; 34: 2151-2159.
14. Choi SH, Ku EJ, Hong ES, et al. High serum adiponectin concentration and low body mass index are significantly associated with increased all-cause and cardiovascular mortality in an elderly cohort, 'adiponectin paradox': the Korean Longitudinal Study on Health and Aging (KLoSHA). Int J Cardiol 2015; 183: 91-97.
15. Sook Lee E, Park SS, Kim E, et al. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol 2013; 42: 1029-1039.
16. Teoh H, Strauss MH, Szmitko PE, et al. Adiponectin and myocardial infarction: a paradox or a paradigm? Eur Heart J 2006; 27: 2266-2268.
17. Sweeney G., Cardiovascular effects of leptin. Nat Rev Cardiol 2010; 7: 22-29.
18. Beltowski J., Leptin and the regulation of endothelial function in physiological and pathological conditions. Clin Exp Pharmacol Physiol 2012; 39: 168-178.
19. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 2140-2144.
20. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
21. Mikkelsen MM, Hansen TK, Gjedsted J, et al. Insulin resistance, adiponectin and adverse outcomes following elective cardiac surgery: a prospective follow-up study. J Cardiothorac Surg 2010; 5: 129.
22. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 1756-1762.
23. Szabó T, Scherbakov N, Sandek A, et al. Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr Metab Cardiovasc Dis 2014; 24: 50-56.
24. Stenvinkel P., Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. J Ren Nutr 2011; 21: 82-86.
25. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-3819.
26. Kadowaki T, Yamauchi T., Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-451.
27. Wang Y, Xu A, Knight C, et al. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem 2002; 277: 19521-19529.
28. Preston SH, Stokes A., Obesity paradox: conditioning on disease enhances biases in estimating the mortality risk of obesity. Epidemiology 2014; 25: 454-461.
29. Wallander M, Söderberg S, Norhammar A., Leptin: a predictor of abnormal glucose tolerance and prognosis in patients with myocardial infarction and without previously known type 2 diabetes. Diab Med 2008; 25: 949-955.
30. Guadagni F, Roselli M, Martini F, et al. Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res 2009; 29: 3321-3327.
31. Seker M, Bilici A, Sonmez B, et al. The association of serum adiponectin levels with histopathological variables in gastric cancer patients. Med Oncol 2010; 27: 1319-1323.